Microbira at GBIP Switzerland, May 2023
We are very excited to announce our selection and participation in Innovate UK’s Global Business Innovation Programme (GBIP) in Switzerland. This initiative focused on Antimicrobial Resistance and brought together leading UK companies to collaborate with Swiss counterparts. They specialise in diagnostics, therapeutics, preventatives, and vaccines
Switzerland’s robust life sciences sector, particularly in the Basel region, is home to over 800 companies. The Swiss approach to combating AMR emphasizes a One Health strategy. It integrates human, animal, and environmental health to address this global challenge comprehensively.
During the five-day innovation visit, our delegation engaged in a series of activities designed to foster collaboration and knowledge exchange. We participated in the 9th AMR Conference in Basel, which provided a platform to connect with key stakeholders, including researchers, policymakers, and industry leaders. This conference is renowned for addressing novel antimicrobials and AMR diagnostics. It aligns perfectly with our mission to advance rapid microorganism identification solutions.
GBIP structure
This is comprised of three main stages:
Get Ready. A preparatory workshop in the UK to build market knowledge and understand cultural aspects of doing business in Switzerland.
Visit the Market. A five-day innovation visit to Switzerland, including meetings with key companies, research organizations, and participation in the AMR Conference.
Exploit the Opportunity. A follow-up workshop and ongoing support from an Innovate UK innovation and growth specialist to maximize the opportunities identified during the visit.
Our involvement in this programme has been instrumental in expanding our international collaborations. It will also enhance our understanding of global AMR strategies. Engaging with Switzerland’s leading experts and institutions equips us to develop innovative diagnostics that address antimicrobial resistance complexities.
Future
We remain committed to leveraging these insights to advance our MAAP-IR technology, aiming to provide rapid and accurate microorganism identification to healthcare providers worldwide. This experience underscores our dedication to combating AMR through international collaboration and innovation.will
